[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-c-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-c-chronic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100434929","treating-hepatitis-c-in-pakistan-strategies-to-avoid-resistance-to-antiviral-drugs-100434929",false,"NCT04943588","Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","Inclusion Criteria:\n\n* Adults over 18yrs old\n* Willing to undergo hepatitis C testing\n* Able and willing to give informed consent\n* Willing to return in 12 months time for repeat testing\n* Resident in area and not planning to leave the region\n\nExclusion Criteria:\n\n* Unwilling to give consent\n* Unwilling or unable to undergo the necessary procedures\n* Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.\n* Co-morbidities limiting life expectancy to less than 12 months",true,"ALL","18 Years","100 Years",{"count":20,"type":21},25000,"ESTIMATED","1 Year","OBSERVATIONAL","We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.",[26],"Hepatitis C, Chronic","RECRUITING","2025-03-21",{"date":30,"type":31},"2025-03-24","ACTUAL",{"date":33,"type":31},"2021-11-01",{"date":35,"type":21},"2026-01-30",{"name":37,"class":38},"Queen Mary University of London","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100506175","digitalized-surveillance-management-for-liver-cancer-risk-population-in-improving-eearly-diagnosis-efficancy-in-chinese-population-dsearch-100506175","NCT05870969","Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)","Exploration of A Holistic Management Procedure for Liver Cancer Surveillance in Improving Liver Cancer's Early Diagnosis Efficacy in Chinese Population: Single-Center, Prospective, Observational Real-world Study in EASTERN China","dSEARCH","Inclusion Criteria:\n\n1. Voluntary participation in the clinical study; fully informed about the study and signed informed consent, willing to follow and capable of completing all trial procedures\\[17\\]\n2. Age: 18 to 75 years old (including the cut-offs)\n3. Subjects must meet at least one of the following criteria for enrollment.\n\n   1. Patients diagnosed with chronic hepatitis B in hospital or out of hospital: persistent positive hepatitis B surface antigen (HBsAg) for 6 months or more\n   2. Patients diagnosed with hepatitis C in hospital or out of hospital\n   3. Patients diagnosed with cirrhosis in hospital or out of hospital who meet at least one of the following criteria.\n\n      1. Liver biopsy showing cirrhosis (Ishak score ≥5 or Metavir score = 4);\n      2. Liver stiffness measurement (LSM) using FibroScan® (Echosens™, Paris, France) ≥12.0 kPa when TB was normal and ALT ≤ 40 IU\u002FmL, or LSM ≥ 17.0 kPa when TB was normal and ALT \\\u003C 200 IU\u002FmL;\n      3. Abdominal imaging results showing characteristic of cirrhosis (results showing coarse liver echotexture or nodular, parenchymal, or morphological abnormalities and signs of gastroesophageal varices);\n      4. APRI ≥ 2.0;\n      5. FIB-4 ≥ 3.25\n   4. Patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) in hospital or out of hospital who have a liver fibrosis score of F3 or higher according to transient elastography, i.e., FibroScan® Liver Stiffness Measurement (LSM) ≥ 10 kPa or the corresponding FibroTouch® measurement threshold\\[18\\].\n\n      * MAFLD diagnosis requires diagnosis of \\>5% fat accumulation in liver through either FibroScan® CAP measurements, or similar parameter, or liver biopsy, and in combination with one of the following three conditions: overweight\u002Fobesity (BMI \\>23 kg\u002Fm2), type 2 diabetes, or metabolic dysfunction.\n   5. Patients diagnosed with MAFLD combined with abnormal glucose metabolism\\[19\\]\n\n      * Abnormal glucose metabolism is defined as type 2 diabetes, or prediabetes, i.e. fasting blood glucose 5.6-6.9 mmol\u002FL, or 2h postprandial blood glucose 7.8-11.0 mmol\u002FL, or glycated hemoglobin 5.7%-6.4%\n   6. Subjects with a family history of liver cancer in their first-degree biological relatives.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n1. Age \\\u003C18 years or \\>75 years\n2. Patients who have been diagnosed with liver cancer before enrollment\n3. Patients with severe mental illness or cognitive impairment\n4. Patients who are pregnant or lactating, or preparing to become pregnant\n5. Patients who have participated in other clinical trials or are participating in other clinical trials within 3 months prior to initiation of study treatment\n6. According to the doctor's judgment, the possibility of the subject being included is low (including inability to understand the project requirements , poor compliance, infirmity, inability to ensure that the protocol can be implemented as required, etc.), or the doctor determines that the subject has any other factors that are not suitable for this study","75 Years",{"count":50,"type":21},20000,"The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.",[53,26,54,55,56],"Carcinoma, Hepatocellular","Hepatitis B, Chronic","Cirrhosis, Liver","Non-Alcoholic Fatty Liver Disease","2023-05-13",{"date":59,"type":31},"2023-05-23",{"date":61,"type":31},"2023-03-01",{"date":63,"type":21},"2028-03",{"name":65,"class":38},"Ruijin Hospital",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":39},"100301154","nation-wide-hepatitis-c-virus-hcv-registry-in-taiwan-100301154","NCT03200379","Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan","Inclusion Criteria:\n\n1\\. Patients who are treated with DAA and have willingness to participate in this registry.\n\nExclusion Criteria:\n\nChronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.",{"count":73,"type":21},150000,"To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan",[26],"2022-04-06",{"date":78,"type":31},"2022-04-08",{"date":80,"type":31},"2017-06-15",{"date":82,"type":21},"2037-06-15",{"name":84,"class":38},"Kaohsiung Medical University Chung-Ho Memorial Hospital"]